The diagnostic value of urinary exosomes in prostate cancer: a prospective multicenter study
Abstract
The diagnosis of prostate cancer (PCa) relies on prostate-specific antigen (PSA) in blood, but the specificity of PSA remains inadequate. This study aims to develop and validate a highly efficient and accurate diagnostic model based on urinary exosomes combined with machine learning (ML) techniques, to identify PCa patients at an early stage and provide support for clinical decision-making. This study included 287 patients from Shanghai Changhai Hospital, Shanghai Shibei Hospital, and Taizhou People’s Hospital, consisting of 89 PCa patients and 198 benign prostatic hyperplasia (BPH) patients. Urinary exosomes were collected from these patients. LASSO regression was used to screen key variables, and nine ML algorithms (including XGBoost, random forest, and logistic regression) were employed to construct the diagnostic model. Model performance was evaluated using AUC, learning curves, calibration curves, and decision curve analysis (DCA), and the contributions of key predictors were visualized using the SHAP method. Among the 11 clinical features included, 3 key features were selected: u-PSA, u-PSMA, and u-AMACR. Among the nine algorithms, the GBDT model performed best, achieving an AUC of 1.000 in the training cohort and 0.987 in the validation cohort. SHAP analysis showed that u-PSA, u-PSMA, and u-AMACR were the most important predictors for PCa. The learning curves indicated that the model fit well and remained stable, while DCA demonstrated significant clinical net…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 287 participants or records.
Read the paper
Related studies
- Pathophysiology of Overactive Bladder and Pharmacologic Treatments Including β3-Adrenoceptor Agonists -Basic Research Perspectives-
- Exosomal Liquid Biopsy in Prostate Cancer: A Systematic Review of Biomarkers for Diagnosis, Prognosis, and Treatment Response
- Leveraging glycosylation for early detection and therapeutic target discovery in pancreatic cancer
- Rethinking of phosphodiesterase 5 inhibition: the old, the new and the perspective in human health
- Long-term outcomes after treatment with Optilume BPH: Four-year results from the EVEREST study
- Future aspects of plant derived bioactive metabolites as therapeutics to combat benign prostatic hyperplasia
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.